EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro

Huan Tang, Zheng Zhang, Ming Zhu, Yizhuo Xie, Zhe Lv, Rui Liu, Yujia Shen, Jin Pei

Pharmaceutics · 19.03.2023 · 15 (3) · 988

DOI: 10.3390/pharmaceutics15030988 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 19.03.2023. Verfasst von Huan Tang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biopharmacy, School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jilin Province Development and Reform Commission, Jilin Science and Technology Department.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is one of the main causes of cancer-related deaths. At present, the main treatment method for lung cancer is chemotherapy. Gemcitabine (GEM) is widely applied in lung cancer treatment, but its lack of targeting ability and serious side effects limit its application. In recent years, nanocarriers have become the focus of research to solve the above problems. Here, we prepared estrone (ES)-modified GEM-loaded PEGylated liposomes (ES-SSL-GEM) for enhanced delivery by identifying the overexpressed estrogen receptor (ER) on lung cancer A549 cells. We studied the characterization, stability, release behavior, cytotoxicity, targeting ability, endocytosis mechanism, and antitumor ability to prove the therapeutic effect of ES-SSL-GEM. The results showed that ES-SSL-GEM presented a uniform particle size of 131.20 ± 0.62 nm, a good stability, and a slowly released behavior. Moreover, ES-SSL-GEM enhanced tumor-targeting ability, and the endocytosis mechanism studies confirmed that the ER-mediated endocytosis had the most crucial effect. Furthermore, ES-SSL-GEM had the best inhibitory effect on A549 cell proliferation and significantly suppressed the tumor growth in vivo. These results suggest that ES-SSL-GEM is a promising agent for treating lung cancer.

Schlagwörter

Stichwörter der Autor:innen

PEGylated liposomeestrogen receptorgemcitabinelung cancertargeting efficiency

Autor:innen und Institutionen

  • Department of Biopharmacy, School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.

Förderung

  • Jilin Province Development and Reform Commission
  • Jilin Science and Technology Department

Zitieren

APA

Tang, H., Zhang, Z., Zhu, M., Xie, Y., Lv, Z., Liu, R., Shen, Y., & Pei, J. (2023). Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro. Pharmaceutics, 15(3), 988. https://doi.org/10.3390/pharmaceutics15030988

Vancouver

Tang H, Zhang Z, Zhu M, Xie Y, Lv Z, Liu R, et al. Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro. Pharmaceutics. 2023;15(3):988. doi:10.3390/pharmaceutics15030988

BibTeX
@article{Tang2023,
  author = {Tang, Huan and Zhang, Zheng and Zhu, Ming and Xie, Yizhuo and Lv, Zhe and Liu, Rui and Shen, Yujia and Pei, Jin},
  title = {Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {3},
  pages = {988},
  doi = {10.3390/pharmaceutics15030988}
}
Kostenlos starten →